Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Prescription opioid availability and opioid overdose‐related mortality rates in Medicaid expansion and non‐expansion states

View through CrossRef
AbstractAimsTo determine whether, in the United States, higher opioid overdose‐related mortality rates (OOMR) in Affordable Care Act (ACA) Medicaid expansion states relative to mortality rates in non‐expansion states have been mediated by increased prescription opioid availability.DesignSeparate mixed‐effect regression models examined difference‐in‐difference effects of time and expansion status on Medicaid‐reimbursed opioids measured in morphine milligram (mg) equivalents on all OOMR and on prescription OOMR. We used generalized structural equation models to test whether increases in Medicaid‐reimbursed prescription opioid availability mediated OOMR post‐Medicaid expansion.Setting and participantsThis study used national, serial, cross‐sectional data for Medicaid‐reimbursed prescription opioids, Medicaid enrollment information and annual OOMR for any opioids and for prescription opioids from 49 states and the DC pre‐ (2008–13) and post‐ACA Medicaid expansion (2014–16).MeasurementsThe outcome measures were OOOMR and Medicaid‐reimbursed prescription opioid availability. The main input variables were time and ACA Medicaid expansion status.FindingsMedicaid expansion states had larger increases in prescription opioid availability (b = 480, 357.8, P = 0.001) compared with non‐expansion states. However, the largest increases in prescription opioid availability in expansion states were between 2009 and 2011, well before the ACA Medicaid expansion. Whereas expansion states also had higher any OOMR compared with non‐expansion states (b = 3.6, P = 0.011), significant differences in prescription OOMR between expansion and non‐expansion states did not emerge until 2015 (b = 1.4, P = 0.014) and 2016 (b = 4.0, P = 0.004), and Medicaid‐reimbursed prescription opioid availability was not a significant mediator.ConclusionsIncreases in Medicaid‐reimbursed prescription opioid availability in Affordable Care Act Medicaid expansion states in the United States do not appear to have mediated post‐Affordable Care Act Medicaid expansion mortality rate differences, but there is still a possibility of lagged effects.
Title: Prescription opioid availability and opioid overdose‐related mortality rates in Medicaid expansion and non‐expansion states
Description:
AbstractAimsTo determine whether, in the United States, higher opioid overdose‐related mortality rates (OOMR) in Affordable Care Act (ACA) Medicaid expansion states relative to mortality rates in non‐expansion states have been mediated by increased prescription opioid availability.
DesignSeparate mixed‐effect regression models examined difference‐in‐difference effects of time and expansion status on Medicaid‐reimbursed opioids measured in morphine milligram (mg) equivalents on all OOMR and on prescription OOMR.
We used generalized structural equation models to test whether increases in Medicaid‐reimbursed prescription opioid availability mediated OOMR post‐Medicaid expansion.
Setting and participantsThis study used national, serial, cross‐sectional data for Medicaid‐reimbursed prescription opioids, Medicaid enrollment information and annual OOMR for any opioids and for prescription opioids from 49 states and the DC pre‐ (2008–13) and post‐ACA Medicaid expansion (2014–16).
MeasurementsThe outcome measures were OOOMR and Medicaid‐reimbursed prescription opioid availability.
The main input variables were time and ACA Medicaid expansion status.
FindingsMedicaid expansion states had larger increases in prescription opioid availability (b = 480, 357.
8, P = 0.
001) compared with non‐expansion states.
However, the largest increases in prescription opioid availability in expansion states were between 2009 and 2011, well before the ACA Medicaid expansion.
Whereas expansion states also had higher any OOMR compared with non‐expansion states (b = 3.
6, P = 0.
011), significant differences in prescription OOMR between expansion and non‐expansion states did not emerge until 2015 (b = 1.
4, P = 0.
014) and 2016 (b = 4.
0, P = 0.
004), and Medicaid‐reimbursed prescription opioid availability was not a significant mediator.
ConclusionsIncreases in Medicaid‐reimbursed prescription opioid availability in Affordable Care Act Medicaid expansion states in the United States do not appear to have mediated post‐Affordable Care Act Medicaid expansion mortality rate differences, but there is still a possibility of lagged effects.

Related Results

Drug overdose among female participants of a harm reduction program in Philadelphia
Drug overdose among female participants of a harm reduction program in Philadelphia
Introduction: In the past two decades, women's rates of fatal drug overdose tripled and nonfatal overdose has been common among women who use illicit drugs. While research has focu...
Buprenorphine Dispensing Following Medicaid Expansion Amid Unwinding in North Carolina
Buprenorphine Dispensing Following Medicaid Expansion Amid Unwinding in North Carolina
Importance The continuous Medicaid enrollment provision adopted during the COVID-19 pandemic ended in March 2023, after which 24 million US residents were disen...
Characterization of opioid overdose and response in a high-risk community corrections sample: A preliminary study
Characterization of opioid overdose and response in a high-risk community corrections sample: A preliminary study
Opiate overdose is an increasingly common cause of death, yet could be easily treated with available opioid antagonists. Opiate use is very common in criminal justice populations, ...
Medicaid Expansion and Severe Maternal Morbidity
Medicaid Expansion and Severe Maternal Morbidity
OBJECTIVE: To evaluate whether there is an association between state-level Medicaid expansion and severe maternal morbidity (SMM) among Medicaid enrollees who d...
Trends in Access to Medications for Opioid Use Disorder
Trends in Access to Medications for Opioid Use Disorder
ImportanceMedicaid, the largest payer for medications for opioid use disorder (MOUD), disenrolled more than 19.1 million individuals by March 2024 after the continuous coverage req...
Patients Perceptions of Opioid Use for Chronic Lower Back Pain in Rural Guatemala
Patients Perceptions of Opioid Use for Chronic Lower Back Pain in Rural Guatemala
Background: Chronic lower back pain is a common cause of disability. Opioids, although not first-line treatment, are often prescribed for chronic lower back pain. The purpose of th...
The Effects of the Medicaid Expansion on Prescription Drug Behavior
The Effects of the Medicaid Expansion on Prescription Drug Behavior
The objective of this empirical exercise was to examine how drug providers in states that implemented the Medicaid expansion in 2014 reacted to the expansion compared with provider...

Back to Top